SCEMBLIX® (asciminib). A targeted approach against CML1
SCEMBLIX is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph + CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors, and without a known T315I mutation.1
An unmet need remains for many CML patients on ≥3rd line of therapy2
The first and only inhibitor Specifically Targeting the ABL1 Myristoyl Pocket (STAMP)3
SCEMBLIX showed superior efficacy vs bosutinib as early as Week 244
SCEMBLIX demonstrated superior efficacy with a well-tolerated safety profile vs a 2nd-generation TKI in the ≥3rd-line setting1,4
CML, chronic myeloid leukaemia; CP, chronic phase; Ph + CML, Philadelphia chromosome-positive chronic myeloid leukaemia; STAMP, specifically targeting the ABL1 myristoyl pocket; TKI, tyrosine kinase inhibitors.
For further information please refer to the Summary of Product Characteristics.
References
SCEMBLIX (asciminib) Summary of Product Characteristics.
Bosi GR, et al. Hematol Transfus Cell Ther 2019;41(3):222–228.
Hughes TP, et al. N Engl J Med 2019;381(24):2315–2326.
Réa D, et al. Blood 2021;138(21):2031–2041.
UK | October 2024 | 443869
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
